Bespak signs new scale-up and commercial supply agreement

Published: 14-Sep-2016
Drug Delivery Medical Devices Pharmaceutical

Pressurised metered dose inhaler technology will be used in respiratory devices to treat COPD


Bespak, part of Consort Medical, and AstraZeneca have signed a multi-year scale-up and commercial supply agreement for Bespak's proprietary pressurised metered dose inhaler (pMDI) valve and actuator technology.

These components will be assembled with AstraZeneca’s Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

AstraZeneca announced that its device was approved by the US Food and Drug Administration on 25 April 2016.

These products will be manufactured in Bespak’s existing King’s Lynn facility. Going forwards the project will be referred to as VAL100.

'We are delighted to have successfully concluded this agreement with AstraZeneca,' said Jon Glenn, Chief Executive Officer of Consort Medical. 'This further reinforces the ongoing strength of our respiratory device franchise in the pMDI segment.'

  • Companies:
  • Bespak
  • AstraZeneca
  • Consort Medical plc
See more

You may also like

Drug Delivery

Bespak and OzUK extend their joint capacity in early-stage pMDI development

Read more
The partnership will streamline the pMDI development, testing and pilot scale manufacturing processes to rapidly progress inhaled therapeutics into clinical trials

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  4. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

Bespak and OzUK extend their joint capacity in early-stage pMDI development

The partnership will streamline the pMDI development, testing and pilot scale manufacturing processes to rapidly progress inhaled therapeutics into clinical trials
Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC
Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Sustainability

Bespak and Orbia Fluor & Energy Materials partner to create climate-friendly inhalers

The two companies will create pMDIs with an optimised sustainability profile with Orbia's low global warming potential (GWP) propellant, Zephex 152a
Regulatory

AstraZeneca's Wainzua recommended for EU approval to treat amyloidosis

The neuropathy drug was developed in tandem with Ionis, and has been shown to reduce neuropathy and increase quality of life in the Phase III NEURO-TTransform trial
Regulatory

AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC

Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Subscribe now